uniQure N.V. (NASDAQ: QURE) Files An 8-K Other Events

ME Staff 8-k
-
0
uniQure N.V. (NASDAQ: QURE) Files An 8-K Other Events

uniQure N.V. (NASDAQ: QURE) Files An 8-K Other Events
Item 8.01. Other Events

On December3, 2018, the Company issued a press release, a copy of which is attached as Exhibit99.1 and is incorporated herein by reference, announcing long-term clinical data from the ongoing Phase I/II trial of AMT-060 and confirming the dose for the AMT-061 pivotal study in Hemophilia B.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

99.1

Press release dated December3, 2018, announcing long-term clinical data from the ongoing Phase I/II trial of AMT-060 and confirming the dose for the AMT-061 pivotal study in Hemophilia B.

EXHIBITINDEX

Exhibit No.

Description

99.1

Press release dated December3, 2018, announcing long-term clinical data from the ongoing Phase I/II trial of AMT-060 and confirming the dose for the AMT-061 pivotal study in Hemophilia B.


uniQure N.V. Exhibit
EX-99.1 2 a18-41023_1ex99d1.htm EX-99.1 Exhibit 99.1     uniQure Announces Long-Term Clinical Data from Ongoing Phase I/II Trial of AMT-060 and Confirms Dose for AMT-061 Pivotal Study in Hemophilia B   — Clinical Benefit of AMT-060 Maintained in All Patients Through up to Two and a Half Years of Follow-up  —   —  Second Dose Cohort Demonstrated a 93% Reduction in FIX Replacement Therapy Usage During Last Twelve Months of Observation,…
To view the full exhibit click here